A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.
Marika TardellaMarco Di CarloMarina CarottiLuca CeccarelliAndrea GiovagnoniFausto SalaffiPublished in: Inflammopharmacology (2022)
Treatment with JAKis or ABA was related to stability or improvement of RA-ILD in 83.9% and 88.6% of patients, respectively. RA duration is the only variable associated with worsening RA-ILD in JAKis-treated patients.